National Patterns of Medication Treatment for Depression, 1987 to 2001
about
Pharmacological interventions for depression in people with traumatic brain injuryMajor depression symptoms in primary care and psychiatric care settings: a cross-sectional analysisAssociation between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trialsAppraisal of the methodological quality and summary of the findings of systematic reviews on the relationship between SSRIs and suicidalityPrenatal antidepressant exposure: clinical and preclinical findings.Fetal effects of psychoactive drugsSafety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution.Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.Treatment of minor depression in older adults: a pilot study comparing sertraline and exerciseIn vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary CareGeneral practitioners' choices and their determinants when starting treatment for major depression: a cross sectional, randomized case-vignette survey.Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderPatient preferences for treatment of major depressive disorder and the impact on health outcomes: a systematic review.Suicide and antidepressants: what current evidence indicates.Review of the epidemiological literature on antidepressant use and breast cancer risk.Use of antidepressant medications in relation to the incidence of breast cancer.Trends in psychotropic medication use among U.S. adults.Novel therapeutic usage of low-dose doxepin hydrochloride.Disparities in detection and treatment history among mothers with major depression in Los Angeles.Use of antidepressants and risk of lung cancer.Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder.Mitotic recombination: a genotoxic effect of the antidepressant citalopram in Aspergillus nidulans.Antidepressant use and breast cancer risk.Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009.A Comparison of Sexual Side Effects of Antidepressants With and Without Naltrexone.Blood transcriptomic markers for major depression: from animal models to clinical settings.Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis.The antidepressant fluoxetine but not citalopram suppresses synapse formation and synaptic transmission between Lymnaea neurons by perturbing presynaptic and postsynaptic machinery.TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design.Moving from empirically supported treatment lists to practice guidelines in psychotherapy: the role of the placebo concept.Escitalopram oxalate, a selective serotonin reuptake inhibitor, exhibits cytotoxic and apoptotic effects in glioma C6 cells.
P2860
Q24200516-A47EF3F5-CE2B-4914-8192-8CAA4A972730Q24288801-5224D953-9310-4161-8D9C-0B03D4A7C186Q24556639-CBAD40A4-89E7-4058-B656-89F00F226756Q26864343-1E56BF61-38FF-49F3-8AC5-8BE706229024Q30415540-232ADF55-0E6E-418F-8316-D124C8F4DF4BQ30479705-A4E2DD86-B99D-42B8-9B93-5C3AE5AB423EQ30990488-99AD976E-4B14-4C8F-9CAF-3B9F3DEB26DEQ33736087-8DFB2907-044C-437A-B2F4-C3F37FBBC865Q33896573-FC760DE8-C16D-41AD-A119-8AC9D61BCBCCQ33910517-ADBA7592-9D63-4EF9-9AD1-6CD19C59770CQ34018843-B17725EC-8C49-41AB-AFF8-E3CCCC68371AQ34323514-963C1F23-CFAE-4667-8BED-6A6069A78CFFQ34526145-18EEC93C-490F-4B45-B6D8-FD00D80BAF22Q34602596-BCAEF3B0-D0A5-4266-A29D-C0C90F46500CQ35205431-438C4EEE-A91A-435F-B67E-3D157387417FQ35702981-65D6697B-037A-4447-9C99-0DEC766C34D9Q35964358-E1A03E5C-ECF7-4D1C-9396-60A2086AF301Q36607352-8A14CFF9-9D3E-48A3-A6B6-0F5279DFDA1BQ36614001-5291C2FA-F302-43F5-911E-862A127495E4Q36730605-C14E4134-22E3-4515-9C0C-64980F8BAD22Q36904871-43161B46-E23B-420B-88E8-2FB336E7345DQ37398274-A67B8564-5BBA-4AB3-B708-06DECD133655Q38461432-C3260F88-034C-43A4-BD3F-17103D2A0E25Q44854643-1E013B64-46B6-4936-9A1C-915B32004C06Q45577882-7639431B-3988-4453-9437-A18BC9C7F40DQ46831629-21B9E693-5DBA-4FFB-9856-0742E7B16F0EQ47890682-7FDD0E12-DF1C-455A-BD45-FC966039FD24Q47894098-D4CC18CE-B72C-4A99-A1E3-01978421C2FDQ48087014-BE0A9645-B307-4E51-930D-B28C589BEAA1Q48643868-B124ED18-F92B-47F8-A333-77802B93819CQ48833768-C5847AB0-21E8-4A6D-93E9-F994D338C494Q51913948-D0B09617-0312-488E-ABD3-2BC9C5BB4A07Q51931182-B853B286-AE1A-43FB-B892-E3C344EAA36DQ55462934-3469D4E2-446F-4A2E-A433-6C17F31B39A9
P2860
National Patterns of Medication Treatment for Depression, 1987 to 2001
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
National Patterns of Medication Treatment for Depression, 1987 to 2001
@ast
National Patterns of Medication Treatment for Depression, 1987 to 2001
@en
type
label
National Patterns of Medication Treatment for Depression, 1987 to 2001
@ast
National Patterns of Medication Treatment for Depression, 1987 to 2001
@en
prefLabel
National Patterns of Medication Treatment for Depression, 1987 to 2001
@ast
National Patterns of Medication Treatment for Depression, 1987 to 2001
@en
P2093
P2860
P356
P1476
National Patterns of Medication Treatment for Depression, 1987 to 2001
@en
P2093
Ellen A. MacDonald
Randall S. Stafford
Stan N. Finkelstein
P2860
P304
P356
10.4088/PCC.V03N0611
P577
2001-12-01T00:00:00Z